CurrentCignaPolicy IP0051

Hyperlipidemia - Omega-3 Fatty Acid Products

Cigna prior authorization policy for prescription coverage of omega-3 fatty acid products (Vascepa and generics/icosapent ethyl capsules) specifying clinical criteria for FDA‑approved and supported uses, duration of approval, preferred product rules for Individual and Family Plans, and exclusions.

Policy Summary

PayerCigna

PolicyHyperlipidemia - Omega-3 Fatty Acid Products

Policy CodePolicy IP0051

Change TypeRevised (annual revision)

Effective Date

Next Review Date

Key ActionPrior Authorization is required for Vascepa (brand and generic); approvals are provided for 1 year when criteria are met.

POLICY UPDATE CHANGES

Updated policy title to Hyperlipidemia - Omega-3 Fatty Acid Products and added examples of cardiovascular disease and risk factors; clarified indications distinguishing FDA‑approved vs supportive evidence.

3Covered Indication Categories

1 yrApproval Duration

IP0051Policy ID

Coverage Summary

This policy (Coverage Policy Number IP0051) describes Cigna prior authorization requirements for icosapent ethyl (Vascepa and bioequivalent generics). The policy stance is covered with criteria; approvals are granted for 1 year when specified clinical criteria are met. The scope covers Vascepa and generic icosapent ethyl capsules and specifies criteria for the FDA‑approved cardiovascular risk reduction indication, severe hypertriglyceridemia (TG ≥ 500 mg/dL), and other supportive hypertriglyceridemia uses (TG 150 mg/dL to < 500 mg/dL).

Medically Necessary Criteria — Icosapent Ethyl (Vascepa, generics)

Medically Necessary Criteria for Icosapent Ethyl (Vascepa, generics)

Icosapent ethyl capsules are considered medically necessary when ONE of the following criteria is met:

ONE of (1, 2, or 3)

Cardiovascular Risk Reduction in a Patient with Elevated Triglycerides
- A) Patient meets one of the following (i or ii)
  - i: Patient has established cardiovascular disease
  - ii
    a: Patient has diabetes
    b: According to the prescriber, patient has at least two additional risk factors for cardiovascular disease.
- B: Prior to initiation of therapy, the patient had a fasting baseline triglyceride level ≥ 150 mg/dL≥ 150 mg/dL (fasting baseline)
- C) Patient meets one of the following (i or ii)
  - i: Patient is receiving statin therapy
  - ii: According to the prescriber the patient cannot tolerate statin therapy
- D: Preferred product criteria is met for the product(s) as listed in the product table [Individual and Family Plans only]
  Approvals are provided for 1 year when criteria are met.
Hypertriglyceridemia with Triglyceride Levels ≥ 500 mg/dL
- A: Prior to initiation of therapy, the patient had a fasting baseline triglyceride level ≥ 500 mg/dL≥ 500 mg/dL (fasting baseline)
- B: Patient has tried, or is currently receiving, one of the following products: niacin (immediate- or extended-release), a fibrate, or a statin.
- C: Preferred product criteria is met for the product(s) as listed in the product table [Individual and Family Plans only]
  Approvals are provided for 1 year when criteria are met.
Other Uses with Supportive Evidence: Hypertriglyceridemia with TG 150 mg/dL to < 500 mg/dL
- A: Prior to initiation of therapy, the patient had a fasting baseline triglyceride level of 150 mg/dL to < 500 mg/dL150 mg/dL to < 500 mg/dL (fasting baseline)
- B: Patient has tried, or is currently receiving, one of the following products: niacin (immediate- or extended-release), a fibrate, or a statin.
- C: Preferred product criteria is met for the product(s) as listed in the product table [Individual and Family Plans only]
  Approvals are provided for 1 year when criteria are met.

Brand versus Generic (Individual & Family Plans)

Individual and Family Plans - Brand versus Generic

Brand (Vascepa) criteria for Individual and Family Plans

Individual and Family Plans - Brand versus Generic: The patient has tried the bioequivalent generic icosapent ethyl capsules, AND cannot take the generic due to a formulation difference in inactive ingredients (e.g., dyes, fillers, preservatives) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

May require prior authorization.

Provider Actions & Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization is required for prescription benefit coverage of Vascepa (icosapent ethyl capsules), both brand and generic. When the patient meets the listed criteria, approvals are provided for 1 year.

Documentation Required

Baseline Fasting Triglyceride Documentation

Provider must document a fasting baseline triglyceride level prior to initiation: ≥ 150 mg/dL for the cardiovascular risk reduction indication; ≥ 500 mg/dL for severe hypertriglyceridemia; or 150 mg/dL to < 500 mg/dL for other supportive hypertriglyceridemia uses.

Documentation Required

Statin Use or Intolerance

For the cardiovascular risk reduction indication (and for some hypertriglyceridemia indications), document that the patient is receiving statin therapy prior to initiation, or provide a prescriber statement that the patient cannot tolerate statin therapy.

Documentation Required

Prior Use of Alternative Products for TG ≥500 or TG 150–499

For triglyceride levels ≥ 500 mg/dL, and for hypertriglyceridemia with TG 150–499 mg/dL (supportive evidence uses), document a trial of, or current use of, niacin (immediate- or extended-release), a fibrate, or a statin prior to initiation.

Documentation Required

Brand vs Generic Justification (Individual & Family Plans)

For Individual and Family Plans when requesting brand Vascepa while a bioequivalent generic exists, document a trial of the generic product and a prescriber rationale that the difference in inactive ingredients (for example, dyes, fillers, preservatives) would cause a significant allergy or serious adverse reaction.

Denial Risk

Not Covered Uses

Claims for icosapent ethyl (Vascepa, generics) that do not meet the specified coverage criteria will be denied as not medically necessary.

Revision History

2024-08-01Annual Revision

Updated policy title to Hyperlipidemia - Omega-3 Fatty Acid Products; added examples of cardiovascular disease and risk factors; clarified indications distinguishing FDA‑approved vs supportive evidence.

2025-05-01Annual RevisionLatest

Policy Summary

PayerCigna

PolicyHyperlipidemia - Omega-3 Fatty Acid Products

Policy CodePolicy IP0051

Change TypeRevised (annual revision)

Effective Date

Next Review Date

Key ActionPrior Authorization is required for Vascepa (brand and generic); approvals are provided for 1 year when criteria are met.

On This Page

OpenPayer

Hyperlipidemia - Omega-3 Fatty Acid Products

Coverage Summary

Medically Necessary Criteria — Icosapent Ethyl (Vascepa, generics)

Brand versus Generic (Individual & Family Plans)

Not Medically Necessary

Provider Actions & Documentation Requirements

Applicable Codes & Identifiers

Clinical Evidence

Background

Revision History